Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AVLNthis companyAvalyn Pharma Inc. Common Stock	$29.41	-14.46×	-5.17×	0×	-12.96×	-95.6%	0.0%	0.0%	0.0%	35.7%	-67.5%	-6.6%	-0.01×	0.56×	0×	10.19×	0.0%	—	—	2	C
GYREGyre Therapeutics, Inc.	$4.69	125.4×	5.95×	5.41×	35.15×	-115.1%	95.4%	9.9%	4.3%	4.7%	5.3%	-0.0%	0.01×	-2.14×	0×	5.6×	0.0%	1	8.69	2	C
INSMInsmed Incorporated	$114.81	-27.15×	50.31×	61.31×	-31.96×	-253.3%	79.4%	-194.0%	-210.5%	-172.8%	-64.8%	-2.6%	1.04×	-0.22×	-14.04×	3.83×	0.0%	4	6.45	1	D+
MNKDMannKind Corporation	$4.14	283.5×	-33.97×	4.97×	77.45×	-1108.3%	82.5%	11.1%	1.7%	-11.5%	5.8%	0.8%	-9.28×	14.48×	2.81×	1.7×	0.0%	1	-4.55	2	C+
PULMPulmatrix, Inc.	$1.39	-1.58×	2.14×	0×	-0.79×	-24.7%	0.0%	0.0%	0.0%	-135.5%	-135.7%	-66.7%	0×	0.79×	0×	12.55×	0.0%	1	-130.04	2	C
Peer median	—	61.91×	4.04×	5.19×	17.18×	-184.2%	80.9%	4.9%	0.8%	-73.5%	-29.8%	-1.3%	0×	0.29×	0×	4.71×	0.0%	1	0.95	2	—